Manuel Crespo

Summary

Affiliation: Hospital Universitari Vall d'Hebron
Country: Spain

Publications

  1. ncbi request reprint Early monitoring of ribavirin serum concentration is not useful to optimize hepatitis C virus treatment in HIV-coinfected patients
    Manuel Crespo
    Infectious Diseases Department, Hospital Universitari Vail d Hebron, Universitat Autonoma de Barcelona, Spain
    Antivir Ther 12:1217-23. 2007
  2. doi request reprint Efficacy of pegylated interferon and ribavirin for retreatment of chronic HCV infection in HIV co-infected patients failing a previous standard interferon-based regimen
    Manuel Crespo
    Infectious Diseases Department, Hospital Universitari Vall d Hebron, Universitat Autonoma de Barcelona, Spain
    J Antimicrob Chemother 62:793-6. 2008
  3. ncbi request reprint Efficacy of recombinant interleukin-2 (rIL-2) in patients with advanced HIV-1 infection and blunted immune response to HAART
    Manuel Crespo
    Infectious Diseases Department, Hospital Universitari Vall d Hebron, Universitat Autonoma de Barcelona, Spain
    Enferm Infecc Microbiol Clin 26:27-31. 2008
  4. ncbi request reprint Utility of week-4 viral response to tailor treatment duration in hepatitis C virus genotype 3/HIV co-infected patients
    Manuel Crespo
    Infectious Diseases Department, Spain
    AIDS 21:477-81. 2007
  5. doi request reprint Response-guided therapy for chronic hepatitis C virus infection in patients coinfected with HIV: a pilot trial
    Eva Van den Eynde
    Infectious Diseases Department, Vall d Hebron Hospital, Autonomous University of Barcelona, Spain
    Clin Infect Dis 48:1152-9. 2009
  6. ncbi request reprint Atazanavir and lopinavir/ritonavir: pharmacokinetics, safety and efficacy of a promising double-boosted protease inhibitor regimen
    Esteban Ribera
    Department of Infectious Diseases, Hospital Universitari Vall d Hebron, Paseo Vall Hebron 119 129, 08035 Barcelona, Spain
    AIDS 20:1131-9. 2006
  7. doi request reprint Changes in body composition and mitochondrial DNA in HIV-1-infected patients switching to fixed-dose abacavir/lamivudine or tenofovir/emtricitabine: a substudy of the BICOMBO trial
    Adrian Curran
    Infectious Diseases Department, Hospital Universitari Vall d Hebron, Universitat Autonoma de Barcelona, Barcelona, Spain
    Antivir Ther 17:711-8. 2012
  8. ncbi request reprint Pharmacokinetic interaction between rifampicin and the once-daily combination of saquinavir and low-dose ritonavir in HIV-infected patients with tuberculosis
    Esteban Ribera
    Infectious Diseases Department, Hospital Universitari Vall d Hebron, Barcelona, Spain
    J Antimicrob Chemother 59:690-7. 2007
  9. doi request reprint Dual therapy based on a ritonavir-boosted protease inhibitor as a novel salvage strategy for HIV-1-infected patients on a failing antiretroviral regimen
    Joaquin Burgos
    Department of Infectious Diseases, Hospital Universitari Vall d Hebron, Universitat Autonoma de Barcelona, Barcelona, Spain
    J Antimicrob Chemother 67:1453-8. 2012
  10. doi request reprint Simplification to dual antiretroviral therapy including a ritonavir-boosted protease inhibitor in treatment-experienced HIV-1-infected patients
    Joaquin Burgos
    Department of Infectious Diseases, Hospital Universitari Vall d Hebron, Universitat Autonoma de Barcelona, Barcelona, Spain
    J Antimicrob Chemother 67:2479-86. 2012

Detail Information

Publications25

  1. ncbi request reprint Early monitoring of ribavirin serum concentration is not useful to optimize hepatitis C virus treatment in HIV-coinfected patients
    Manuel Crespo
    Infectious Diseases Department, Hospital Universitari Vail d Hebron, Universitat Autonoma de Barcelona, Spain
    Antivir Ther 12:1217-23. 2007
    ..Therefore, it has been suggested that monitoring RBV serum levels could be used to drive dose modification and to optimize management of HCV-infected patients receiving combination treatment...
  2. doi request reprint Efficacy of pegylated interferon and ribavirin for retreatment of chronic HCV infection in HIV co-infected patients failing a previous standard interferon-based regimen
    Manuel Crespo
    Infectious Diseases Department, Hospital Universitari Vall d Hebron, Universitat Autonoma de Barcelona, Spain
    J Antimicrob Chemother 62:793-6. 2008
    ..However, data available on the efficacy of this therapy in co-infected patients who failed a former interferon-based regimen are limited...
  3. ncbi request reprint Efficacy of recombinant interleukin-2 (rIL-2) in patients with advanced HIV-1 infection and blunted immune response to HAART
    Manuel Crespo
    Infectious Diseases Department, Hospital Universitari Vall d Hebron, Universitat Autonoma de Barcelona, Spain
    Enferm Infecc Microbiol Clin 26:27-31. 2008
    ..The primary endpoint was median change in CD4+ T-cell counts at the end of treatment as compared to baseline. Secondary endpoints were safety and changes in the various T-cell subpopulations...
  4. ncbi request reprint Utility of week-4 viral response to tailor treatment duration in hepatitis C virus genotype 3/HIV co-infected patients
    Manuel Crespo
    Infectious Diseases Department, Spain
    AIDS 21:477-81. 2007
    ..To investigate the utility of a week-4 virological response for sustained response prediction in hepatitis C virus (HCV) genotype 3/HIV-co-infected patients treated with interferon and ribavirin for 24 weeks...
  5. doi request reprint Response-guided therapy for chronic hepatitis C virus infection in patients coinfected with HIV: a pilot trial
    Eva Van den Eynde
    Infectious Diseases Department, Vall d Hebron Hospital, Autonomous University of Barcelona, Spain
    Clin Infect Dis 48:1152-9. 2009
    ..To study the feasibility of a response-guided therapy for chronic hepatitis C virus (HCV) infection in patients coinfected with human immunodeficiency virus (HIV) in a tertiary care hospital...
  6. ncbi request reprint Atazanavir and lopinavir/ritonavir: pharmacokinetics, safety and efficacy of a promising double-boosted protease inhibitor regimen
    Esteban Ribera
    Department of Infectious Diseases, Hospital Universitari Vall d Hebron, Paseo Vall Hebron 119 129, 08035 Barcelona, Spain
    AIDS 20:1131-9. 2006
    ..To assess the pharmacokinetics and tolerability of lopinavir (LPV), ritonavir (RTV) and atazanavir (ATV) as a double-boosted protease inhibitor regimen in HIV-infected adults...
  7. doi request reprint Changes in body composition and mitochondrial DNA in HIV-1-infected patients switching to fixed-dose abacavir/lamivudine or tenofovir/emtricitabine: a substudy of the BICOMBO trial
    Adrian Curran
    Infectious Diseases Department, Hospital Universitari Vall d Hebron, Universitat Autonoma de Barcelona, Barcelona, Spain
    Antivir Ther 17:711-8. 2012
    ....
  8. ncbi request reprint Pharmacokinetic interaction between rifampicin and the once-daily combination of saquinavir and low-dose ritonavir in HIV-infected patients with tuberculosis
    Esteban Ribera
    Infectious Diseases Department, Hospital Universitari Vall d Hebron, Barcelona, Spain
    J Antimicrob Chemother 59:690-7. 2007
    ..To assess plasma steady-state pharmacokinetics (PK) of rifampicin, isoniazid, saquinavir and ritonavir in HIV and tuberculosis (TB) co-infected patients, and investigate potential interactions between TB drugs and protease inhibitors (PIs)...
  9. doi request reprint Dual therapy based on a ritonavir-boosted protease inhibitor as a novel salvage strategy for HIV-1-infected patients on a failing antiretroviral regimen
    Joaquin Burgos
    Department of Infectious Diseases, Hospital Universitari Vall d Hebron, Universitat Autonoma de Barcelona, Barcelona, Spain
    J Antimicrob Chemother 67:1453-8. 2012
    ..To assess the efficacy and safety of dual-antiretroviral therapy containing a ritonavir-boosted protease inhibitor (PI/r) in treatment-experienced patients failing a current antiretroviral regimen...
  10. doi request reprint Simplification to dual antiretroviral therapy including a ritonavir-boosted protease inhibitor in treatment-experienced HIV-1-infected patients
    Joaquin Burgos
    Department of Infectious Diseases, Hospital Universitari Vall d Hebron, Universitat Autonoma de Barcelona, Barcelona, Spain
    J Antimicrob Chemother 67:2479-86. 2012
    ..To assess the effectiveness of simplification to a dual antiretroviral regimen containing a ritonavir-boosted protease inhibitor (PI/r) in treatment-experienced HIV-1-infected patients...
  11. doi request reprint Ability of treatment week 12 viral response to predict long-term outcome in genotype 1 hepatitis C virus/HIV coinfected patients
    Eva Van den Eynde
    Infectious Diseases Service, Hospital Vall d Hebron, Medicine Department, Universitat Autonoma de Barcelona, Spain
    AIDS 24:975-82. 2010
    ..Our main objective was to study the ability of week 12 viral response [early virologic response (EVR)] to predict long-term outcome in patients treated for 48 weeks...
  12. doi request reprint Improvements in subcutaneous fat, lipid profile, and parameters of mitochondrial toxicity in patients with peripheral lipoatrophy when stavudine is switched to tenofovir (LIPOTEST study)
    Esteban Ribera
    Department of Infectious Diseases, Hospital Universitari Vall d Hebron, Barcelona, Spain
    HIV Clin Trials 9:407-17. 2008
    ..Lipoatrophy is the most stigmatizing side effect of stavudine therapy. We assessed the long-term effects of replacing stavudine with tenofovir in HIV-infected patients with lipoatrophy...
  13. doi request reprint Body composition changes after switching from protease inhibitors to raltegravir: SPIRAL-LIP substudy
    Adrian Curran
    Hospital Universitari Vall d Hebron, Universitat Autonoma de Barcelona, Infectious Diseases Department, Spain
    AIDS 26:475-81. 2012
    ..To compare 48-week changes in body fat distribution and bone mineral density (BMD) between patients switching from a ritonavir-boosted protease inhibitor (PI/r) to raltegravir (RAL) and patients continuing with PI/r...
  14. pmc Steady-state pharmacokinetics of a double-boosting regimen of saquinavir soft gel plus lopinavir plus minidose ritonavir in human immunodeficiency virus-infected adults
    Esteban Ribera
    Servicio de Enfermedades Infecciosas, Hospital Universitari Vall d Hebron, Paseo Vall Hebron 119 129, 08035 Barcelona, Spain
    Antimicrob Agents Chemother 48:4256-62. 2004
    ....
  15. doi request reprint Abacavir coadministration does not interfere with the suppressive activity of ribavirin in an HCV replicon system
    Eva Van den Eynde
    Infectious Diseases Department, Vall d Hebron Hospital, Universitat Autonoma de Barcelona, Barcelona, Spain
    Antivir Ther 16:887-93. 2011
    ..Here, we studied the effect of abacavir, tenofovir or lamivudine addition on the suppressive activity of ribavirin in an HCV RNA replicon system...
  16. doi request reprint Efficacy, safety and pharmacokinetics of 900/100 mg of darunavir/ritonavir once daily in treatment-experienced patients
    Adrian Curran
    Infectious Diseases Department, Hospital Vall d Hebron, Autonomous University of Barcelona, Barcelona, Spain
    J Antimicrob Chemother 65:2195-203. 2010
    ..To evaluate the virological efficacy, safety, tolerability and pharmacokinetics of a regimen containing 900/100 mg of ritonavir-boosted darunavir once daily in patients with antiretroviral experience but no darunavir resistance...
  17. doi request reprint Effectiveness and safety of didanosine, lamivudine and efavirenz versus zidovudine, lamivudine and efavirenz for the initial treatment of HIV-infected patients from the Spanish VACH cohort
    Manuel Crespo
    Hospital Universitari Vall d Hebron, Barcelona, Spain
    J Antimicrob Chemother 63:189-96. 2009
    ..In an observational study, we analyse the efficacy and tolerability of didanosine plus lamivudine and efavirenz versus zidovudine plus lamivudine and efavirenz in a cohort of therapy naive patients...
  18. pmc Tropical diseases screening in immigrant patients with human immunodeficiency virus infection in Spain
    Fernando Salvador
    Infectious Diseases Department, Hospital Universitari Vall d Hebron, Universitat Autonoma de Barcelona, Spain
    Am J Trop Med Hyg 88:1196-202. 2013
    ..We propose a screening and management strategy of latent parasitic infections in immigrant patients infected with HIV...
  19. pmc Ultrasensitive real-time PCR for the clinical management of visceral leishmaniasis in HIV-Infected patients
    Israel Molina
    Infectious Disease Department, Universitat Autonoma de Barcelona, Barcelona, Spain
    Am J Trop Med Hyg 89:105-10. 2013
    ..9%. Monitoring parasite load by an ultrasensitive quantitative Leishmania PCR is useful to predict the risk of relapse after a VL episode in HIV-infected patients...
  20. ncbi request reprint Effectiveness of ritonavir-boosted protease inhibitor monotherapy in the clinical setting: same results as in clinical trials? The PIMOCS Study Group
    Adrian Curran
    Infectious Diseases Department, Hospital Universitari Vall d Hebron, Universitat Autonoma de Barcelona, Barcelona, Spain
    J Antimicrob Chemother 69:1390-6. 2014
    ..Here, we analyse the effectiveness and safety of PIMT in clinical practice...
  21. ncbi request reprint Tuberculous trochanteric bursitis: report of 5 cases and literature review
    Manuel Crespo
    Hospital Universitari Vall d Hebron, Universitat Autonoma, Barcelona, Spain
    Scand J Infect Dis 36:552-8. 2004
    ..This report presents 5 new cases of TTB and a review of the literature (1981-2003), with emphasis on clinical and radiological findings and treatment, in order to investigate the optimum therapeutic approach...
  22. doi request reprint Invasive pneumococcal disease in HIV-infected adults: clinical changes after the introduction of the pneumococcal conjugate vaccine in children
    Joaquin Burgos
    Department of Infectious Diseases, Hospital Universitari Vall d Hebron, Universitat Autonoma de Barcelona, Spain
    J Acquir Immune Defic Syndr 59:31-8. 2012
    ..We conducted a multicenter study to analyze differences in clinical presentation of IPD between HIV-infected and non-HIV-infected adults in the prevaccine and postvaccine era...
  23. ncbi request reprint Efficacy of ampicillin combined with ceftriaxone and gentamicin in the treatment of experimental endocarditis due to Enterococcus faecalis with no high-level resistance to aminoglycosides
    Joan Gavalda
    Infectious Diseases Research Laboratory, Infectious Diseases Division, Hospital Universitari Vall d Hebron, Universitat Autonoma de Barcelona, Avda Vall d Hebron, 119 129, 08035 Barcelona, Spain
    J Antimicrob Chemother 52:514-7. 2003
    ..It also determines whether adding ceftriaxone to ampicillin and gentamicin increases the effectiveness against experimental enterococcal endocarditis resulting from E. faecalis...
  24. ncbi request reprint Lactic acidosis related to nucleoside therapy in HIV-infected patients
    Vicenc Falco
    Infectious Diseases Division, Hospital Universitari Vall d Hebron, Universitat Autonoma de Barcelona, P masculine Vall d Hebron 119 129 08035, Barcelona, Spain
    Expert Opin Pharmacother 4:1321-9. 2003
    ..Therapy is based on supportive measures and discontinuation of all antiretroviral drugs. Administration of essential vitamin coenzymes, electron acceptors and L-carnitine may be useful in some cases...
  25. ncbi request reprint Metabolic benefits 24 months after replacing a protease inhibitor with abacavir, efavirenz or nevirapine
    Cesar Fisac
    Nutrition Section, Hospital Universitari de Bellvitge, L Hospitalet de Llobregat, Barcelona, Spain
    AIDS 19:917-25. 2005
    ..To evaluate the 24-month metabolic and morphological benefits obtained from replacing the protease inhibitor (PI) in a regimen with nevirapine, efavirenz or abacavir...